588 related articles for article (PubMed ID: 28434398)
21. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
22. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
Spain L; Larkin J
Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
[No Abstract] [Full Text] [Related]
23. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
[TBL] [Abstract][Full Text] [Related]
24. The benefits of immunotherapy combinations.
Schmidt C
Nature; 2017 Dec; 552(7685):S67-S69. PubMed ID: 29293245
[No Abstract] [Full Text] [Related]
25. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
[TBL] [Abstract][Full Text] [Related]
26. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
Chang X; Lu X; Guo J; Teng GJ
Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
[TBL] [Abstract][Full Text] [Related]
27. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Elia AR; Caputo S; Bellone M
Front Immunol; 2018; 9():1786. PubMed ID: 30108594
[TBL] [Abstract][Full Text] [Related]
28. Novel Immunologic Approaches to Melanoma Treatment.
Escandell I; Martín JM; Jordá E
Actas Dermosifiliogr; 2017 Oct; 108(8):708-720. PubMed ID: 28527857
[TBL] [Abstract][Full Text] [Related]
29. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
30. Systemic Therapies for Advanced Melanoma.
Bomar L; Senithilnathan A; Ahn C
Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint blockade after kidney transplantation.
Lesouhaitier M; Dudreuilh C; Tamain M; Kanaan N; Bailly E; Legoupil D; Deltombe C; Perrin P; Manson G; Vigneau C; Houot R
Eur J Cancer; 2018 Jun; 96():111-114. PubMed ID: 29705511
[No Abstract] [Full Text] [Related]
32. Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model.
Padrón Á; Hurez V; Gupta HB; Clark CA; Pandeswara SL; Yuan B; Svatek RS; Turk MJ; Drerup JM; Li R; Curiel TJ
Exp Gerontol; 2018 May; 105():146-154. PubMed ID: 29326088
[TBL] [Abstract][Full Text] [Related]
33. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Kumar P; Bhattacharya P; Prabhakar BS
J Autoimmun; 2018 Dec; 95():77-99. PubMed ID: 30174217
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016.
Taquin H; Fontas E; Massol O; Chevallier P; Balloti R; Beranger G; Lacour JP; Passeron T; Montaudié H
Ann Dermatol Venereol; 2018 Nov; 145(11):649-658. PubMed ID: 30098818
[TBL] [Abstract][Full Text] [Related]
36. Clinical deployment of antibodies for treatment of melanoma.
Curti BD; Urba WJ
Mol Immunol; 2015 Oct; 67(2 Pt A):18-27. PubMed ID: 25746916
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
38. [Modern methods of immunotherapy for metastatic melanoma].
Novik AV; Baldueva IA; Protsenko SA; Nekhaeva TL; Semenova AI; Danilova AB; Latipova DK; Anokhina EM; Komarov YI; Akhaeva ZY
Vopr Onkol; 2016; 62(5):580-587. PubMed ID: 30695581
[TBL] [Abstract][Full Text] [Related]
39. Combination Immunotherapy Development in Melanoma.
Eggermont AMM; Crittenden M; Wargo J
Am Soc Clin Oncol Educ Book; 2018 May; 38():197-207. PubMed ID: 30231333
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of Melanoma.
Tarhini AA
Curr Mol Pharmacol; 2016; 9(3):196-207. PubMed ID: 26177647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]